Today it was reported that the Chief Operating and of Bluebird Bio (BLUE), Jason Cole, exercised options to buy 562 BLUE shares at $50.51 a share, for a total transaction value of $28.39K.
Following Jason Cole’s last BLUE Buy transaction on January 09, 2019, the stock climbed by 14.2%. Following this transaction Jason Cole’s holding in the company was increased by 2.13% to a total of $3.36 million.
See today’s analyst top recommended stocks >>
Currently, Bluebird Bio has an average volume of 742.4K.
Based on 10 analyst ratings, the analyst consensus is Moderate Buy with an average price target of $157.00, reflecting a 25.3% upside. Five different firms, including BMO Capital and Cowen & Co., currently also have a Buy rating on the stock.
Company insider trades are published daily on the SEC (Securities and Exchange Commission). DailyInsider’s proprietary algorithm analyzes these trades and selects the most attractive stocks based on influential insider trades each day. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
bluebird bio, Inc. is a clinical-stage biotechnology company, which engages in the development of potential gene therapies for severe genetic diseases and cancer. Its integrated product platform includes gene therapy, cancer immunotherapy, and gene editing. Its product pipeline includes Lenti-D, LentiGlobin, BCL11a shRNA, bb2121, and bb21217.
